This is the peer reviewd version of the followng article:

Conversion of Robotic Distal Pancreatectomy: Predictors and Outcomes in an International Multicenter Study / Muller, P.C., Sedlaczek, P., Billeter, A.T., Shen, B., Jin, J., Nickel, F., Guidetti, C., Kauffmann, E., Purchla, J., Berchtold, C., Tschuor, C., Krohn, P.S., Burgdorf, S.K., Jonas, J.P., Bussmann, F.J., Saint-Marc, O., Iben-Khayat, A., Andel, P.C.M., Molenaar, I.Q., Wellner, U., et al.. - In: ANNALS OF SURGERY. - ISSN 0003-4932. - (2025), pp. 1-10. [10.1097/SLA.0000000000006821]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

16/10/2026 23:20

(Article begins on next page)

Annals of Surgery Publish Ahead of Print
DOI:10.1097/SLA.0000000000006821

OPEN

Conversion of Robotic Distal Pancreatectomy: Predictors and Outcomes in an International Multicenter Study

Philip C. Müller*, MD[1], Philipp Sedlaczek*, MD[1], Adrian T. Billeter, MD, PhD[1], Baiyong Shen, MD[2], Jiabin Jin, MD[2], Felix Nickel, MD, MME[3], Cristiano Guidetti, MD[4], Emanuele Kauffmann, MD[5], Julia Purchla, MD[6], Caroline Berchtold, MD[1], Christoph Tschuor, MD, PhD[7], Paul Suno Krohn, MD, PhD[7], Stefan K. Burgdorf, MD, PhD[7], Jan Philipp Jonas, MD, PhD[8], Felix Julius Bussmann[8], Olivier Saint-Marc, MD[9], Abdallah Iben-khayat, MD[9], Paul C.M. Andel MD[10], Izaak Quintus Molenaar, MD[10], Ulrich Wellner, MD[11], Tobias Keck, MD[11], Beat Moeckli, MD[12], Christian Toso, MD[12], Fabrizio Di Benedetto, MD[4], Valentina Valle, MD[13], Pier Giulianotti, MD[13], Didier Roulin, MD[14,15], John Martinie, MD[14], Martina Rama, MD[16], Harish Lavu, MD[16], Charles J. Yeo, MD[16], Parit T. Mavani, MD[17], Mihir M. Shah, MD[17], David A. Kooby, MD[17], Jin He, MD[6], Ugo Boggi, MD[5], Thilo Hackert, MD[3], Inne H.M. Borel-Rinkes MD[10], Pierre-Alain Clavien, MD, PhD[8], Beat P. Müller, MD[1], Christoph Kuemmerli, MD, MSc[1]

1 Department of Surgery, Clarunis University Digestive Health Care Center, University Hospital Basel, Basel, Switzerland
2 Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Research Institute of Pancreatic Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4 Hepato-pancreato-biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy
5 Division of General and Transplant Surgery, University of Pisa, Pisa, Italy
6 Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, USA
7 Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ACCEPTED

8 Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland
9 Service de Chirurgie Digestive, Endocrinienne et Thoracique, Centre Hospitalier Régional, Orleans, France
10 Department of Hepato-Pancreato-Biliary Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital Nieuwegein and University Medical Center Utrecht, the Netherlands
11 Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
12 Department of Surgery, University Hospital of Geneva, Geneva, Switzerland
13 Division of General, Minimally Invasive, and Robotic Surgery, Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA
14 Division of HPB Surgery, Department of Surgery, Carolinas Medical Center, Charlotte, USA
15 Department of Visceral Surgery, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland
16 Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA
17 Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

*These authors contributed equally

Corresponding Author
Philip C. Müller
Department of Surgery, Clarunis University Digestive Health Care Center, University Hospital Basel
Spitalstrasse 21
4031 Basel
Switzerland
e-mail: philip.mueller@clarunis.ch

Short running head
Impact of Conversion in Robotic Distal Pancreatectomy

Author contributions
PS and PCM: conception and design, interpretation of data, creation of figures, drafting of article, and final approval. CK: conception and design, acquisition of data, statistical analysis, interpretation of data, creation of figures, drafting of article, and final approval. ATB, BS, JJ, FN, CG, EK, JP, CT, PSK, SKB, JPJ, OSM, AI, PCMA, IQM, UW, TK, BM, CT, FDB, VV, PG, DR, JM, MR, HL, CY, PTM, MMS, DAK, JH, UB, TH, IHMB, BPM: conception and design, interpretation of data, critical revision of the article, and final approval. Data supporting this study's findings are available on request from the corresponding author.

Conflict of interest

ACCEPTED

The authors declare no conflicts of interest. This study did not receive any grants or other external financial support.

Abstract

Objective

The aim of this study was to identify risk factors for conversion and assess its consequences on clinical outcomes after robotic distal pancreatectomy (RPD).

Summary of Background Data

RDP has gained popularity due to its lower conversion rate (3-8%) when compared to laparoscopic distal pancreatectomy (10-20%).

Methods

This retrospective multicenter study included RDPs performed at 16 international centers from May 2007 to March 2024. Perioperative outcomes of patients requiring conversion were compared to fully robotic RDP patients. Risk factors for conversion were identified by multivariable logistic regression analysis.

Results

Of 2,452 patients undergoing RDP, 75 (3.1%) required conversion to open surgery. In converted RDPs, operative time was longer (300 (243–376) vs. 180 (120–240) minutes; p<0.001), and blood loss was greater (500 (200–990) vs. 100 (50–200) ml; p<0.001). Converted patients experienced more overall complications (53% vs. 39%; p=0.017), major complications (41% vs. 25%; p<0.001), and a higher 90-day mortality (5% vs. 3%; p<0.001). Furthermore, both postoperative pancreatic fistula (35% vs. 18%; p<0.001) and delayed gastric emptying (10% vs. 3%; p<0.001) were more frequent in the conversion group. The rate of patients achieving textbook outcome was lower after conversion (57% vs. 74%; p=0.003). In the multivariable analysis, lesion size (>51mm; OR 2.86 (95% CI 1.56-5.08)), BMI (>28kg/m^2; OR 3.03 (1.75-5.30)), previous abdominal surgery (OR 2.48 (1.31-4.51)), patients outside benchmark criteria (OR 2.09 (1.19-3.72)), and age (>62 years; OR 2.21 (1.24-4.05)) were associated with conversion.

Conclusion

This international cohort study confirmed a very low conversion rate for RDP. Yet, converted cases experienced substantially impaired postoperative outcomes, highlighting the need for adequate patient selection through validated difficulty scoring systems.

ACCEPTED

Key words:
Robotic surgery; pancreatic surgery; distal pancreatectomy; conversion; clinical outcomes.

Abbreviations

ASA	American Society of Anesthesiologists
CCI	Comprehensive Complication Index
CD	Clavien-Dindo
DGE	Delayed Gastric Emptying
DP	Distal Pancreatectomy
EBL	Estimated Blood Loss
ISGPS	International Study Group of Pancreatic Surgery
LDP	Laparoscopic Distal Pancreatectomy
LOS	Length of Hospital Stay
MIPS	Minimally Invasive Pancreatic Surgery
OT	Operative Time
PACE	Pancreatic Surgery Composite Endpoint
PDAC	Pancreatic Ductal Adenocarcinoma
POPF	Postoperative Pancreatic Fistula
PPH	Postpancreatectomy Hemorrhage
RDP	Robotic Distal Pancreatectomy
TBO	Textbook Outcome

ACCEPTED

Introduction

Minimally invasive surgery has become the standard approach for most distal pancreatectomies (DP)[1–4]. Due to its superior short-term outcomes and comparable oncological results, minimally invasive pancreatic surgery (MIPS) for left-sided pathology has been established as the preferred approach for both benign and malignant indications[1,2,5]. Traditionally, MIPS has been performed laparoscopically but, recently, robotic distal pancreatectomy (RDP) has been rapidly adopted due to its advantageous learning curve and lower conversion rates compared to the laparoscopic approach[3,6,7]. Especially in technically difficult cases including malignant indications with proximity to large vessels, RDP seems to pose clear advantages over LDP with its superior versatility of surgical instruments and 3D vision[8].

Reported conversion rates from MIPS to open surgery are around 12% for all pancreatic procedures, while higher conversion rates are reported for the laparoscopic approach and malignant indications[5,9–12]. Conversions are often divided into planned and emergency conversions for reasons including adhesions, uncontrolled bleeding, vascular tumor involvement, and concerns for oncological radicality[5,9,11,13–15]. For LDP, general preoperative risk factors for conversion have been identified and include obesity, malignancy, and chronic pancreatitis. Furthermore, intraoperative risk factors include multi-organ resections and tumor proximity to vascular structures [9,14,16]. While extensive evidence exists on the impact of conversion in LDP, conversion during RDP with its associated risk factors and impact on postoperative outcomes have been poorly investigated and large, multicenter studies from high volume centers are noticeably lacking.

The aim of this study, therefore, is to identify risk factors associated with conversion of RDP and to analyze its impact on perioperative outcome within a consecutive patient series from 16 international centers with expertise in RDP.

Methods

Study Design

The study is reported according to the STROBE guidelines [17]. Sixteen high volume centers performing >50 pancreatic resections/year with a minimum experience of 40 RDPs were included. The final *Outcomes4RDP* collaborative consortium included: 10 centers from Europe (Basel, Copenhagen, Geneva, Heidelberg, Orléans, Lübeck, Modena, Pisa, Utrecht, and Zurich), five centers from the USA (Atlanta, Baltimore, Charlotte, Chicago, and Philadelphia), and one center from Asia (Shanghai)[6]. Patients operated on from the first RDP

ACCEPTED

performed at each center until March 2024 were included. Ethical approval from the institutional board was obtained (BASEC ID 2023-01497).

Indication for RPD

Patients undergoing RDP with or without splenectomy for benign and malignant pancreatic diseases localized in the pancreatic body or tail, without involvement of the venous or arterial axis (Type 1 DP)[18], were included.

Data collection and outcomes

Data were retrieved from prospectively-maintained institutional databases and stored in an anonymized and secure online data management system. In addition to basic demographics, clinically relevant comorbidities (body mass index (BMI), diabetes, chronic obstructive pulmonary disease (COPD), chronic renal failure (CRF), and cardiac disease) were collected. Benchmark patients were defined as low-risk patients without significant comorbidities according to the international benchmark study[4]. In detail, exclusion criteria for benchmark cases were American Society of Anesthesiologists grade >2, chronic renal failure (Modification of diet in Renal Disease Study Group Stage >3), chronic obstructive pulmonary disease with forced expiratory volume <80% or anticoagulative medication.

Intraoperative outcomes included estimated blood loss (EBL), operative time (OT) and rate of unplanned splenectomies. Conversion was defined according to the Brescia Guidelines as an unplanned open incision apart from the incision needed for specimen extraction and further divided in planned and emergency conversion[19].

Postoperative complications were assessed using the Clavien-Dindo (CD) classification and the Comprehensive Complication Index (CCI®) to quantify the number and severity of complications for each patient up to 90 days after surgery[20–22]. Major complications were defined as CD grade IIIa or higher. Additional outcomes evaluated included reoperation rate, postoperative length of hospital stay (LOS), 90-day readmission rate, and 90-day mortality rate.

Pancreas-specific complications were defined according to the International Study Group of Pancreatic Surgery (ISGPS) and included postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), and post pancreatectomy hemorrhage (PPH)[23–25]. Textbook outcome (TBO) was defined by the absence of POPF, bile leak, PPH (ISGPS grade B/C), major complications, readmission, and in-hospital mortality and reflects optimal surgical results after DP[26]. Similar to the TBO, the Pancreatic Surgery Composite Endpoint (PACE) has been developed as a standardized measure to assess outcomes following pancreatic surgery. The PACE is considered positive if one of the following postoperative complications

ACCEPTED

is present: POPF, PPH, reoperation, or reintervention. The PACE can be used to predict prolonged hospital stays and perioperative mortality[27]. To assess volume-outcome relationships, we divided centers as low or high-volume according to an annual caseload of 25 RDP.

For patients with pancreatic ductal adenocarcinoma (PDAC), the following oncologic outcomes were reported: R0 resection rate [28], lymph node harvest, and need for adjuvant chemotherapy.

Conversion Risk Score

De Ponthaud et al. introduced the preoperative conversion risk score (CRS) for minimally invasive DP. The CRS consists of six variables: male sex, body mass index >25kg/m^2, previous laparotomy, pancreatitis as initial symptom, tumor size (>40mm), and splenectomy. The CRS ranges from 0 to 7 and corresponded to a risk of conversion from 2% to 100% [29]. The accuracy of the CRS was tested in the current cohort.

Statistical analysis

Descriptive statistics were used to display the perioperative cohort characteristics. Qualitative variables were expressed as frequencies and percentages. Quantitative variables were expressed as mean and standard deviation (SD) if normally distributed and as median and interquartile range (IQR) when otherwise. Means between groups were compared with Student's t-test (pooled t-test) or the nonparametric Mann-Whitney. To compare percentages between groups, a contingency table analysis using the chi-square or Fisher's exact test was used when the frequency of events was low. To assess a volume effect, centers with less than 25% benchmark cases were compared to centers with a higher percentage of benchmark cases.

Logistic regression was then used to assess the association between predictor variables and conversion. A stepwise backward variable selection based on Aikake information criterion (AIC) was used for variable selection. Clinically relevant variables (tumor size, BMI, previous surgery, and PDAC vs. no PDAC) were fitted to the model. Multiple imputation was used to address the missing at random of tumor size and BMI for the multivariable model by using predictive mean matching. Dichotomization of predictor variables was used to aid clinical applicability. To assess impact, an additional model was run using the continuous predictor variables.

ACCEPTED

All analyses were performed using R version 4.2.3, R Core Team (2023) (R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).

Results

Patient demographics

A total of 2,452 patients undergoing RDP were included in the study. 75 patients (3.1%) required conversion to open surgery, with 63 (2.6%) planned and 9 (0.4%) emergency conversions. The annual conversion rates of the cohort are shown in supplementary figure 1, Supplemental Digital Content 1, http://links.lww.com/SLA/F533. For three patients, the reason for urgency was unavailable. The reason for conversion in the remaining cases included bleeding (n=23), adhesions (n=14), oncological reasons (n=13), technical difficulties (n=13), visceral fat (n=9), and various (n=12). Converted patients were older (65 (55-73) vs. 59 (45-68) years; p=0.001), had a higher BMI (27 (24-31) vs. 24 (22-27) kg/m²; p=0.001), and more comorbidities. (**Table 1**).

Impact on intraoperative outcomes

Conversion was associated with a prolonged OT (300 (243–376) vs. 180 (120–240) minutes; p<0.001), higher EBL (500 (200–990) vs. 100 (50– 200; p < 0.001)), and a higher rate of unplanned splenectomies (6.9% vs. 0.6%; p<0.001) (**Table 2**). There were no differences in OT (325 (213–401) vs. 296 (245–375) minutes) and EBL (900 (325–1125) vs. 500 (200–945) ml) between planned and emergency conversions.

Impact on postoperative outcomes

Converted patients experienced a higher rate of overall (53% vs. 39%; p=0.017) and major complications (42% vs. 25%; p<0.001). Mortality was almost doubled in case of conversion (5% vs. 3%; p<0.001). Pancreas-specific complications such as POPF (36% vs. 19%; p<0.001) and DGE (12% vs. 3%; p<0.001) were both more frequent in the conversion group. The higher complication rate led to more reinterventions (20% vs. 4%; p<0.001) and readmissions (15% vs. 8%; p=0.058); however, reoperation rate (5% vs. 3%; p=0.384) did not differ. In converted patients with PDAC, an R0 resection was achieved in a similar proportion of patients (85% vs. 92%, p=0.505), but in converted cases lymph node yield was higher (19 (13-23) vs. 9 (4-17), p=0.001)

Looking at modern composite outcomes, the proportion of patients with a positive PACE was doubled in the conversion group (39% vs. 22%; p=0.003) and, in line with this

ACCEPTED

finding, fewer patients achieved a TBO in the conversion group (57% vs. 74%; p=0.003) (**Table 2**).

Between planned and emergency conversions, there was no differences in major complications (22% vs. 22%; p=0.472), POPF (33% vs. 37%; p=1.000), reoperation rate (19% vs 19%; p=0.908) and mortality (0% vs. 3.1%; p=1.000).

Risk factors for conversion

In the multivariable analysis, age over 62 years, BMI over 28 kg/m^2, previous upper abdominal surgery, lesions larger than 51mm, and being a high risk, non-benchmark patient were significant independent factors associated with an increased conversion risk. (**Table 3**).

Furthermore, higher case volumes in overall robotic pancreatic procedures (1.9% vs. 11.8%) and RDP (0.7% vs. 6.7%) were shown to reduce conversion rates (**Figure 1**).

Conversion risk score

The CRS showed low discrimination in the RDP cohort and overestimated the conversion rate in low- and high-risk patients. For example, up to a CRS of 4 points, the actual RDP conversion rate was below 4%, while the CRS suggests a 35% risk of conversion in this cohort (**Figure 2**).

Discussion

This international multicenter study highlights a very low conversion rate of 3.1% in 2,452 patients undergoing RDP from 16 expert centers. Postoperative outcomes following conversion were significantly impaired compared to successfully completed robotic DP. For example, in converted cases, blood loss was five times higher, more unplanned splenectomies were performed, while the rate of major complications increased threefold and postoperative mortality doubled. Converted patients likewise experienced a higher incidence of pancreas-specific complications such as POPF and DGE. These clinically relevant differences underline the consequences of converted MIDP, highlighting the importance of adequate patient selection for MIPS. However, it remains unclear whether these inferior outcomes are primarily due to the initial surgical approach, the inherent complexity of the converted cases, or a combination of both. These uncertainties further emphasize the need for validated difficulty scoring systems for RDP, similar to the robotic pancreatoduodenectomy score (PD-

ACCEPTED

ROBOSCORE)[30] and ISGPS complexity grading system [31,32], which have recently been established for pancreaticoduodenectomy.

Conversions can be divided into two groups: emergency and planned. While the former are almost always due to uncontrolled bleeding and are associated with worse outcomes, planned conversions are mainly due to technical reasons such as vascular tumor involvement, oncologic concerns, difficult visualization, or adhesions [9,33–36]. In the current series, only 9 conversions were emergencies, making meaningful comparisons difficult. However, 7 of these conversions were due to uncontrolled bleeding. The largest up-to-date analysis on the topic includes patients from the American College of Surgeons National Surgical Quality Improvement Program and compared outcomes from 958 LDPs, 323 RDP to 231 converted MIDPs, and 1,414 open DPs. In line with the results of our cohort, conversion led to longer OT, increased overall and major complication rates, as well as more reoperations compared to both MIDP and ODP. Furthermore, compared to the MIDP group, 30-day mortality was significantly higher in case of conversion (0.3% vs. 2.2%)[14,30,31]. A recent meta-analysis also found impaired outcomes for converted minimally invasive pancreatic head resections in comparison to MIPD, suggesting that patient selection according to surgical complexity is of paramount importance in minimally invasive pancreatic head and body/tail resections[37].

In line with the higher rate of perioperative complications, modern composite endpoints stress the favorable postoperative outcomes and patient recovery of successfully completed RDP with a higher rate of patients achieving TBO (74% vs. 57%) and less patients with a positive PACE (22% vs. 39%). Those results are comparable to the MIDP TBO rates of 60%-70% reported in the literature [26,38,39]. Both TBO and PACE are clinically relevant composite endpoints that summarize adverse events. Moreover, the 20% difference in the current cohort highlights the potential for lower sample sizes for future prospective trials in MIPS as compared to single metric endpoints (e.g. POPF).

Regarding oncologic safety, we found that conversion had no impact on the R0 rate but lymph node harvest was higher in case of conversion, albeit within the benchmark cutoff of at least 9 lymph nodes for both groups. Furthermore, fewer converted patients with PDAC were able to receive adjuvant chemotherapy (74% vs. 50%). Unfortunately, no data were available for the current cohort to assess the impact of higher lymph node harvest and lower rate of adjuvant chemotherapy on long-term survival. The influence of the conversion on long-term PDAC outcomes should be assessed within the *Outcomes4RDP collaborative* in a

ACCEPTED

follow-up study. However, a large multicenter study assessed the impact of conversion in patients with PDAC undergoing LDP. The reason for conversion was almost equally split among three groups: vascular tumor involvement, oncological concerns, and bleeding. Converted PDAC patients had a lower R0 resection rate (58% vs. 72%) a higher recurrence rate (72% vs. 55%), and a trend towards lower median overall survival (21 vs. 32 months) when compared to laparoscopically completed DP. However, since tumor proximity to vascular structures (<1cm) was the most relevant risk factor for conversion and 2/3 of all conversions were performed for oncologic reasons, the need for conversion may just as easily reflect a more advanced disease stage [40]. Therefore, their oncologic results should be interpreted with caution. In a second step, the authors compared converted cases to a matched open cohort and found similar oncologic results, stating that the inferior oncologic results rather reflect a more aggressive disease than the act of conversion [41].

Still, surgeons should be aware of their own skills and learning curve, especially when operating on anatomically difficult-to-resect PDAC or when encountering unexpected findings [42]. In such cases, an early and planned conversion should be considered to prevent serious events such as bleeding and emergency conversion. As shown in this and other studies, emergency conversion significantly impacts postoperative outcomes and consequently the chance to receive adjuvant chemotherapy. Several studies on pancreatic surgery highlight the importance of severe morbidity (and its consequently reduced rate of patients receiving adjuvant treatment) on long-term survival [43–45].

Recently, the Heidelberg group classified DP into 4 types according to level of technical difficulty. The extent of resection and taking into consideration portal vein, arterial, and multivisceral resections correlated with both intra- and postoperative outcomes and can be considered a basis for difficulty assessment in open and minimally-invasive DP[18]. A more detailed difficulty scoring system for LDP originating in Japan includes five factors: type of operation, pancreatic transection line, tumor proximity to major vessels, tumor extension to peripancreatic tissue, and left-sided portal hypertension. Based on this score, the authors suggest assigning cases to surgeons according to their level of experience. For example, a resection with a high difficulty score of 7-10 points should be reserved for proficient surgeons with an experience of 50 LDPs or more [46]. In an external validation cohort, the Japanese difficulty scoring system was shown to strongly correlate with intraoperative outcomes such as conversion rate, OT, and intraoperative blood loss [47]. While a comparable difficulty measurement for RDP is missing, several preoperative factors have been found to increase the level of surgical difficulty for RDP, namely tumors located at the neck of the pancreas and the

ACCEPTED

origin of the splenic artery within the pancreatic parenchyma [48]. In the current multivariable analysis, age, BMI, lesion size, previous upper abdominal surgery, and being outside of the benchmark criteria were preoperative risk factors for conversion. We recommend to adjust the case selection according to modifiable risk factors (BMI, tumor size and previous abdominal surgery), especially in the early individual learning curve.

The recently introduced CRS aimed to classify the risk of conversion in minimally invasive DP based on six preoperatively available parameters (male sex, BMI, previous laparotomy, pancreatitis, tumor size, and planned splenectomy). In their internal evaluation, the CRS performed similarly in both the training (AUC=0.75) and validation sets (AUC=0.74). While the authors included mainly LDPs (87%) and a small proportion of RDPs (13%) for a combined MIDP conversion risk score, the main advantage of RDP was found to be a conversion rate that is three times lower. This finding has been repeatedly documented by international benchmark studies. The benchmark cutoff was 3-5% for RDP and 15-20% for LDP[4,49–51]. The differing conversion benchmark values highlight the importance of an adequate reference cutoff when interpreting the CRS (**Figure 2**). In the current RDP cohort, the CRS showed low discrimination and overestimated the true conversion rate regardless of patient risk level. Although BMI, increasing tumor size and previous surgery are risk factors for conversion in both the present analysis and the CRS, the variables were defined differently. More importantly, the robotic approach may facilitate solving difficult intraoperative situations and ultimately alter the conversion pattern. We therefore advise against applying the CRS to RDP.

Surgical experience has a significant effect on both patient selection and surgical outcomes. In the current study, conversion rates were markedly lower in high-volume RDP centers as defined by an annual case load of more than 25 RDPs. The nationwide LAELAPS training program for MIDP from the Dutch Pancreatic Cancer Group consisted of a detailed technique description, video training, and on-site proctoring. In their initial evaluation, 32 pancreatic surgeons were trained in MIDP and while more advanced tumors were successfully resected after the training program, the conversion rate could be lowered impressively from 38% to 8% [52]. In line with those findings, both surgeon volume and institutional experience were shown to impact the conversion rate in patients undergoing LDP [53,54]. For RDP, the different learning phases of competency, proficiency, and mastery were recently[6]. While the different phases of the institutional learning curve were reached relatively late (after 46 to 73 procedures), the conversion rate did not meaningfully decrease from 5.2% to 3.8%. Still, compared to LDP, the robotic approach offers a 10-15% reduced conversion rate, which

ACCEPTED

translates to clinically relevant benefits in terms of morbidity and recovery for a large cohort of patients.

This study poses some limitations, due not only to its retrospective nature but because important information on the reason and timing of some conversions could not be retrieved. Furthermore, this study does not compare the outcomes of converted cases to an open cohort to assess the true value of the robotic approach. However, several randomized studies show the benefits of MIDP. In addition, due to the low conversion rate, the small size of the converted RDP group limits statistical comparison.

In conclusion, this international, multicenter cohort study found that conversion rates for RDP are low overall. Furthermore, a conversion from the robotic to an open approach has a relevant influence on clinical outcomes in terms of major morbidity and mortality. In obese patients with anatomically difficult-to-resect PDACs in particular, upcoming studies should focus on appropriate patient selection for the robotic approach and should, consequently, evaluate the effects of RDP on long-term oncologic outcomes.

Compliance with Ethical Standards

Conflict of interest: The authors declare that they have no conflict of interest.

Source of Funding: The study was funded by institutional means.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval was obtained from the ethical review board of the University of Basel (BASEC ID 2023-01497).

Informed consent: Not applicable due to the nature of the study design.

ACCEPTED

References

1. Pfister M, Probst P, Müller PC, et al. Minimally invasive versus open pancreatic surgery: meta-analysis of randomized clinical trials. *BJS Open*.;7 . Epub ahead of print March 7, 2023. DOI: 10.1093/bjsopen/zrad007.

2. Korrel M, Vissers FL, van Hilst J, et al. Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trials. *HPB (Oxford)*. 2021;23:323–330.

3. Jehan FS, Khreiss M, Seth A, et al. Trends and disparities in access to minimally invasive distal pancreatectomy (midp): an eight-year analysis from the national cancer database. *J Robot Surg*. 2024;18:52.

4. Müller PC, Breuer E, Nickel F, et al. Robotic distal pancreatectomy: A novel standard of care? Benchmark values for surgical outcomes from 16 international expert centers. *Ann Surg*. 2023;278:253–259.

5. Korrel M, Jones LR, van Hilst J, et al. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. *Lancet Reg Health Eur*. 2023;31:100673.

6. Müller PC, Kuemmerli C, Billeter AT, et al. Competency, proficiency, and mastery: Learning curves for robotic distal pancreatectomy at 16 international expert centers. *Ann Surg*. . Epub ahead of print November 19, 2024. DOI: 10.1097/SLA.0000000000006592.

7. Müller PC, Kuemmerli C, Cizmic A, et al. Learning curves in open, laparoscopic, and robotic pancreatic surgery: A systematic review and proposal of a standardization. *Ann Surg Open*. 2022;3:e111.

8. Ausania F, Gonzalez-Abós C, Landi F, et al. Conversion to open surgery in obese patients undergoing minimally invasive distal pancreatectomy: results from a multicenter analysis. *HPB (Oxford)*. 2024;26:1172–1179.

9. Balduzzi A, van der Heijde N, Alseidi A, et al. Risk factors and outcomes of conversion in minimally invasive distal pancreatectomy: a systematic review. *Langenbecks Arch Surg*. 2021;406:597–605.

10. Rompianesi G, Montalti R, Giglio M, et al. Robotic versus laparoscopic surgery for spleen-preserving distal pancreatectomies: Systematic review and meta-analysis. *Ann Hepatobiliary Pancreat Surg*. 2022;26:S244–S244.

11. Liu R, Liu Q, Zhao Z-M, et al. Robotic versus laparoscopic distal pancreatectomy: A propensity score-matched study. *J Surg Oncol*. 2017;116:461–469.

12. Kamarajah SK, Sutandi N, Robinson SR, et al. Robotic versus conventional laparoscopic distal pancreatic resection: a systematic review and meta-analysis. *HPB (Oxford)*. 2019;21:1107–1118.

13. Suman P, Rutledge J, Yiengpruksawan A. Robotic distal pancreatectomy. *JSLS*. 2013;17:627–635.

14. Nassour I, Wang SC, Porembka MR, et al. Conversion of minimally invasive distal pancreatectomy: Predictors and outcomes. *Ann Surg Oncol*. 2017;24:3725–3731.

ACCEPTED

15. Chen C, Lin X, Lin R, et al. An evidence-based model for predicting conversion to open surgery in minimally invasive distal pancreatectomy. *Surg Endosc*. . Epub ahead of print September 3, 2024. DOI: 10.1007/s00464-024-11216-9.

16. Cipriani F, Berardi G, Barkhatov L, et al. Conversion unfavorable intraop- erative events results significantly worse outcomes during lapa- roscopic liver resection: lessons learned from multicenter review 2861 cases. *Ann Surg*. 2018;268:1051–1057.

17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg*. 2014;12:1495–1499.

18. Loos M, Mack CE, Xu ATL, et al. Distal pancreatectomy: Extent of resection determines surgical risk categories. *Ann Surg*. 2024;279:479–485.

19. Abu Hilal M, van Ramshorst TME, Boggi U, et al. The Brescia Internationally Validated European Guidelines on Minimally Invasive Pancreatic Surgery (EGUMIPS). *Ann Surg*. 2024;279:45–57.

20. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 2009;250:187–196.

21. Dindo D, Clavien P-A. What is a surgical complication? *World journal of surgery*. 2008;32:939–941.

22. Clavien P-A, Vetter D, Staiger RD, et al. The comprehensive complication index (CCI®): Added value and clinical perspectives 3 years "down the line." *Ann Surg*. 2017;265:1045–1050.

23. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. *Surgery*. 2017;161:584–591.

24. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery*. 2007;142:761–768.

25. Wente MN, Veit JA, Bassi C. Postpancreatectomy hemorrhage (PPH): International Study Group Pancreatic Surgery (ISGPS) definition. Surgery. *Surgery*.;142.

26. van Roessel S, Mackay TM, van Dieren S, et al. Textbook outcome: Nationwide analysis of a novel quality measure in pancreatic surgery. *Ann Surg*. 2020;271:155–162.

27. Nickel F, Kuemmerli C, Müller PC, et al. The PAncreatic surgery Composite Endpoint (PACE): Development and validation of a clinically relevant endpoint requiring lower sample sizes. *Ann Surg*. 2025;281:496–500.

28. Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. *Br J Surg*. 2018;105:1171–1181.

29. De Ponthaud C, Nassar A, Dokmak S, et al. Conversion during minimally invasive left pancreatectomy: A nationwide study of causes and consequences. *Ann Surg*. . Epub ahead of print February 28, 2025. DOI: 10.1097/SLA.0000000000006685.

ACCEPTED

30. Napoli N, Cacace C, Kauffmann EF, et al. The PD-ROBOSCORE: A difficulty score for robotic pancreatoduodenectomy. *Surgery*. 2023;173:1438–1446.

31. Barreto SG, Strobel O, Salvia R, et al. Complexity and experience grading to guide patient selection for minimally invasive pancreatoduodenectomy. *Ann Surg*. 2025;281:417–429.

32. Napoli N, Donisi G, Kauffmann EF, et al. External validation of the ISGPS complexity grading system for minimally invasive pancreatoduodenectomy: Insights from the IGOMIPS registry. *Ann Surg*. . Epub ahead of print December 18, 2024. DOI: 10.1097/SLA.0000000000006612.

33. AlMasri S, Kwon W, Lee K, et al. Reasons for conversion by experienced surgeons differ for laparoscopic and robotic distal pancreatectomy; a multi-institutional analysis. *HPB (Oxford)*. 2021;23:S530–S531.

34. van Bodegraven EA, van Ramshorst TME, Bratlie SO, et al. Minimally invasive robot-assisted and laparoscopic distal pancreatectomy in a pan-European registry a retrospective cohort study. *Int J Surg*. 2024;110:3554–3561.

35. van Ramshorst TME, van Bodegraven EA, Zampedri P, et al. Robot-assisted versus laparoscopic distal pancreatectomy: a systematic review and meta-analysis including patient subgroups. *Surg Endosc*. 2023;37:4131–4143.

36. Li P, Zhang H, Chen L, et al. Robotic versus laparoscopic distal pancreatectomy on perioperative outcomes: a systematic review and meta-analysis. *Updates Surg*. 2023;75:7–21.

37. Karunakaran M, Marshall-Webb M, Ullah S, et al. Impact of unplanned intra-operative conversions on outcomes in minimally invasive pancreatoduodenectomy. *World J Surg*. 2023;47:2507–2518.

38. Villodre C, Del Río-Martín J, Blanco-Fernández G, et al. Textbook outcome in distal pancreatectomy: A multicenter study. *Surgery*. 2024;175:1134–1139.

39. Radulova-Mauersberger O, Mibelli N, von Bechtolsheim F, et al. Textbook outcome after pancreatoduodenectomy and distal pancreatectomy with postoperative hyperamylasemia-a propensity score matching analysis. *J Gastrointest Surg*. 2024;28:451–457.

40. Kauffmann EF, Napoli N, Di Dato A, et al. Practical implications of tumor proximity to landmark vessels in minimally invasive radical antegrade modular pancreatosplenectomy. *Updates Surg*. 2023;75:1533–1540.

41. Lof S, Korrel M, van Hilst J, et al. Outcomes of elective and emergency conversion in minimally invasive distal pancreatectomy for pancreatic ductal adenocarcinoma: An international multicenter propensity score-matched study. *Ann Surg*. 2021;274:e1001–e1007.

42. Napoli N, Ginesini M, Kauffmann EF, et al. Navigating the learning curve of robotic pancreatoduodenectomy: Competency, proficiency, and mastery in a first-generation robotic surgeon with established open pancreatic expertise. *Surgery*. 2025;109347.

ACCEPTED

43. Sandini M, Ruscic KJ, Ferrone CR, et al. Major complications independently increase long-term mortality after pancreatoduodenectomy for cancer. *J Gastrointest Surg*. 2019;23:1984–1990.

44. Russell TB, Labib PL, Ausania F, et al. Serious complications of pancreatoduodenectomy correlate with lower rates of adjuvant chemotherapy: Results from the recurrence after Whipple's (RAW) study. *Eur J Surg Oncol*. 2023;49:106919.

45. Macfie R, Berger Y, Liu H, et al. Major postoperative complications limit adjuvant therapy administration in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma or pancreatic ductal adenocarcinoma. *Ann Surg Oncol*. 2023;30:5027–5034.

46. Ohtsuka T, Ban D, Nakamura Y, et al. Difficulty scoring system in laparoscopic distal pancreatectomy. *J Hepatobiliary Pancreat Sci*. 2018;25:489–497.

47. Deiro G, De Pastena M, Paiella S, et al. Assessment of difficulty in laparoscopic distal pancreatectomy: A modification of the Japanese difficulty scoring system - A single-center high-volume experience. *J Hepatobiliary Pancreat Sci*. 2021;28:770–777.

48. Xu Q, Li P, Zhang H, et al. Identifying the preoperative factors predicting the surgical difficulty of robotic distal pancreatectomy. *Surg Endosc*. 2023;37:3823–3831.

49. Giani A, van Ramshorst T, Mazzola M, et al. Benchmarking of minimally invasive distal pancreatectomy with splenectomy: European multicentre study. *Br J Surg*. 2022;109:1124–1130.

50. Müller PC, Toti JMA, Guidetti C, et al. Benchmarking outcomes for distal pancreatectomy: critical evaluation of four multicenter studies. *Langenbecks Arch Surg*. 2023;408:253.

51. Durin T, Marchese U, Sauvanet A, et al. Defining benchmark outcomes for distal pancreatectomy: Results of a French multicentric study. *Ann Surg*. 2023;278:103–109.

52. de Rooij T, van Hilst J, Boerma D, et al. Impact of a nationwide training program in minimally invasive distal pancreatectomy (LAELAPS). *Ann Surg*. 2016;264:754–762.

53. Goh BKP, Chan CY, Lee SY, et al. Factors associated with and consequences of open conversion after laparoscopic distal pancreatectomy: initial experience at a single institution. *ANZ J Surg*. 2017;87:E271–E275.

54. Hua Y, Javed AA, Burkhart RA, et al. Preoperative risk factors for conversion and learning curve of minimally invasive distal pancreatectomy. *Surgery*. 2017;162:1040–1047.

ACCEPTED

Figure 1: Impact of center specific annual case load of robotic pancreatic surgery (A) and robotic distal pancreatectomy (B). Centers were classified as high-volume if the caseload was over 25 procedures.



ACCEPTED

Figure 2: Conversion rate of the robotic distal pancreatectomy cohort (red) and the mainly laparoscopic cohort of the original publication (blue). Furthermore, international benchmark cutoffs for the conversion rate of laparoscopic (yellow) and robotic (green) distal pancreatectomy are depicted.



ACCEPTED

Table 1: Baseline characteristics of patients undergoing robotic distal pancreatectomy.

		Conversion		
	Overall	**No**	**Yes**	***P***
	(n= 2'452)	(n= 2'377)	(n= 75)	
Age, years	59 (46-69)	59 (45-68)	65 (56-73)	0.001
Male	1001 (41.2)	962 (40.8)	39 (52.7)	0.053
Benchmark cases*	1626 (67.0)	1601 (68.0)	25 (34.2)	<0.001
BMI, kg/m^2	24 (22-27)	24 (22-27)	27 (23-31)	0.001
ASA ≥ 3	604 (25)	567 (24)	37 (50)	<0.001
Diabetes	458 (18.8)	439 (18.6)	19 (26.0)	0.148
COPD	66 (2.7)	61 (2.6)	5 (6.8)	0.148
CRF	39 (1.6)	36 (1.5)	3 (5.2)	0.070
Cardiac disease	239 (9.8)	224 (9.5)	15 (20.3)	0.004
Anticoagulants	226 (9.3)	212 (9.0)	14 (18.9)	0.007
Smoking	491 (21.5)	463 (20.8)	28 (43.7)	<0.001
Neoadjuvant Therapy	64 (2.8)	62 (2.7)	2 (2.9)	0.284
Lesion size, mm	30 (20-45)	30 (20-44)	36 (20-60)	0.236
Duct diameter >3mm	277 (38.8)	257 (38.1)	20 (50.3)	0.207
Diagnosis				<0.001
PDAC	623 (25.6)	602 (25.5)	21 (28.0)	
NET	524 (21.5)	514 (21.8)	10 (13.3)	
IPMN	273 (11.2)	260 (11.0)	13 (13.7)	
Chronic pancreatitis	72 (3.0)	66 (2.8)	6 (8.0)	
Cystic lesions	844 (34.6)	824 (34.8)	20 (26.7)	
Other benign	49 (2.0)	48 (2.0)	1 (1.3)	
Other malignant	52 (2.1)	48 (2.0)	4 (4.3)	

Note: Data are given as n (%) and median (IQR). ASA, American Society of Anesthesiologists; BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; CRF, Chronic Renal Failure; IPMN, Intraductal Papillary Mucinous Neoplasm; NET, Neuroendocrine Tumor; PDAC, Pancreatic Ductal Adenocarcinoma.
*low-risk patients according to Müller et al.[4]

ACCEPTED

Table 2: Intra- and postoperative outcomes for robotic distal pancreatectomy cases.

		Conversion		
	Overall (n= 2452)	**No** (n=2377)	**Yes** (n=75)	***P***
Duration, min	180 (120-247)	180 (120-240)	300 (243-376)	<0.001
Blood loss, ml	100 (50-200)	100 (50-200)	500 (200-990)	<0.001
Splenectomy				<0.001
Planned	1327 (57)	1288 (57)	39 (54)	
Unplanned	18 (0.8)	13 (0.6)	5 (6.9)	
Intraoperative drain	2343 (97)	2276 (97)	67 (97)	1.000
Time to drain removal, days	7 (5-11)	7 (5-11)	8 (5-14)	0.136
Overall complications	962 (39)	922 (39)	40 (53)	0.017
Highest CD complication				0.001
2	161 (16.6)	148 (16.0)	13 (31.7)	
3a	113 (11.7)	104 (11.2)	9 (22.0)	
3b	84 (8.7)	81 (8.7)	3 (7.3)	
4a	15 (1.5)	13 (1.4)	2 (4.9)	
4b	6 (0.6)	5 (0.5)	1 (2.4)	
5	28 (2.9)	26 (2.8)	2 (4.9)	
Major complication (CD≥3a)	246 (25.4)	229 (24.6)	17 (41.5)	<0.001
POPF				<0.001
Grade B	452 (18.8)	427 (18.3)	25 (34.7)	
Grade C	14 (0.6)	13 (0.6)	1 (1.4)	
DGE				<0.001

ACCEPTED

A	34 (1.4)	30 (1.3)	4 (5.3)	
B	29 (1.2)	26 (1.1)	3 (4.0)	
C	7 (0.3)	5 (0.2)	2 (2.7)	
PPH				0.599
Grade B	18 (0.7)	17 (0.7)	1 (1.3)	
Grade C	41 (1.7)	41 (1.7)	0 (0.0)	
ERCP	52 (2.1)	49 (2.1)	3 (4.1)	0.451
Percutaneous drain	105 (4.3)	90 (3.8)	15 (20.3)	<0.001
Reoperation	73 (3.0)	69 (2.9)	4 (5.3)	0.384
LOS, days	14 (7-20)	14 (7-20)	10 (7-15)	0.016
Readmission	198 (8.1)	187 (7.9)	11 (14.7)	0.058
CCI at discharge	0 (0-8.7)	0 (0- 8.7)	8.70 (0-25.3)	<0.001
CCI after 3months	0 (0-8.7)	0 (0-8.7)	8.70 (0-26.9)	<0.001
PACE	534 (22.5)	509 (22.1)	25 (38.5)	0.003
TBO	1762 (73.5)	1723 (74.0)	39 (57.4)	0.003
Pancreatic adenocarcinoma (n=623)				
Lymph node harvest	9 (4-17)	9 (4-17)	19 (13-23)	0.001
Positive lymph nodes	0(0-1)	0 (0-1)	1 (0-2)	0.077
R0 resection	557 (91.8)	540 (92.0)	17 (85.0)	0.505
Adjuvant chemotherapy	351 (73.1)	343 (73.9)	8 (50.0)	0.066

Note: Data are given as n (%) and median (IQR).
CD, Clavien-Dindo; CCI, Comprehensive Complication Index; ERCP, Endoscopic Retrograde Cholangiopancreatography; LOS, Length of Stay; PACE, Pancreatic Surgery Composite Endpoint; POPF, Postoperative Pancreatic Fistula; PPH, Postpancreatectomy Hemorrhage; TBO, Textbook Outcome.

ACCEPTED

Table 3: Multivariable Regression Analysis

	Multivariable	
	OR (95% CI)	***P***
Intercept	0.24 (0.12–0.43)	<0.001
Age >62y	2.21 (1.24-4.05)	0.010
BMI >28 kg/m^2	3.03 (1.75-5.30)	<0.001
Previous upper abdominal surgery	2.48 (1.31-4.51)	0.047
PDAC	1.1 (0.58–2.02)	0.755
Size >51mm	2.86 (1.56-5.08)	<0.001
Non-benchmark patient	2.09 (1.19-3.72)	0.005

BMI, Body Mass Index; OR, Odds Ratio; PDAC, Pancreatic Ductal Adenocarcinoma.

ACCEPTED